[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pelvic-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pelvic-tumor":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100548226","contribution-of-3d-modeling-in-surgical-management-of-pediatric-retroperitoneal-and-pelvic-tumors-100548226",false,"NCT06418243","Contribution of 3D Modeling in Surgical Management of Pediatric Retroperitoneal and Pelvic Tumors","Non-interventional Study on the Contribution of 3D Modelling in Surgical Management of Pediatric Retroperitoneal and Pelvic Tumors Compared to 2D Imaging","3D-PEDSURG","Inclusion Criteria:\n\nChildren:\n\n* Children between 3 months and less than 18 years old\n* Children with a pelvic tumor requiring an MRI for a possible surgical intervention\n* Children with a retroperitoneal tumor requiring a CT scan or MRI with a view to surgical intervention\n* Children with no contraindication for a CT scan and\u002For 3T MRI\n* Children whose parents do not object to their participation in the study\n\nOther participants:\n\n* Operating surgeon agreeing to participate in the study\n* Caregiver agreeing to participate in the study\n* External surgeon agreeing to participate in the study\n\nExclusion Criteria:\n\nChildren :\n\n* Contraindication to MRI: metallic ocular foreign body, pacemaker, mechanical heart valve, old vascular clips on cerebral aneurysm\n* Need for an MRI under general anaesthesia\n* Contraindication for a CT scan with injection: renal failure, allergy to iodinated contrast products\n* Patients having participated in a therapeutic clinical trial involving a new molecule within 30 days before inclusion\n* Emergency situation","ALL","3 Months","17 Years",{"count":21,"type":22},60,"ESTIMATED","OBSERVATIONAL","This study's purpose is the comparison of the automatically segmented 3D model to the reference manual segmentation, based on the Dice precision index. It is implemented by making parents' patients, surgeons and surgical helpers answer specific questions comparing 3D images to usual 2D images of the patient's tumor.",[26,27],"Pelvic Tumor","Retroperitoneal Tumor",[29,30,31,32,33,34],"Surgery","3D-Imaging","MRI","CT Scan","Paediatric surgery","Tumor","RECRUITING","2026-03-19",{"date":38,"type":39},"2026-03-23","ACTUAL",{"date":41,"type":39},"2024-09-16",{"date":43,"type":22},"2026-09",{"name":45,"class":46},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100530306","pelvic-cancer-registry-for-online-adapted-radiotherapy-100530306","NCT06185062","Pelvic Cancer Registry for Online Adapted Radiotherapy","Pelvic and Thoracic Cancer Treated With Online Adapted Radiotherapy: A Prospective Registry-based Phase-II Trial","PRoART","INCLUSION CRITERIA\n\n* Patients with pelvic or thoracic tumors with an indication for radiotherapy\n* Patient information and declaration of consent\n* Patients age ≥ 18 years\n\nEXCLUSION CRITERIA\n\n* Prior radiotherapy in affected site","18 Years",{"count":58,"type":22},846,"5 Years","This prospective registry-based trial will include patients with pelvic or thoracic tumors with an indication for radiotherapy treated with oART or IGRT. For the primary endpoint and the secondary clinical endpoints, the trial will compare oART versus IGRT, for technical endpoints the trial will compare the real oART scenario with two virtual (hypothetical) control scenarios.\n\nPrimary endpoint:\n\n* 10% reduction in the rate of acute radiotherapy related toxicity (≥ CTCAE II°, v5.0) using oART\n\nSecondary endpoints:\n\n* Clinical endpoints: Tumor control, late toxicities compared to conventional irradiated patients, quality of life and patient-reported outcomes\n* Technical endpoints: Target volume, target coverage, dose to organs at risk, anatomical variability score",[26,62],"Thoracic Tumor",[64],"online Adaptive Radiotherapy","2024-02-06",{"date":67,"type":39},"2024-02-08",{"date":69,"type":39},"2024-01-01",{"date":71,"type":22},"2030-04",{"name":73,"class":46},"University Medical Center Goettingen"]